Clinical Competition Candidate
ZOKINVY
ZOKINVY carries use-code patent, low complexity (1/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 37 months away. Active clinical competition may compress the generic entry window.
LOE window
37months
to latest listed patent expiry (July 26, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 1
Complexity score: 1/5
Clinical competition
Score: 4/5
Active trials linked: 42
Phase 2/3 trials: 27
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: LONAFARNIB
Applicant (NDA holder): SENTYNL THERAPEUTICS INC
Confidence: High